Pancreatic Cancer Research

Journal articleEur J Pharmacol2023

CASP1 is a target for combination therapy in pancreatic cancer.

Journal
Eur J Pharmacol
Published
8 November 2023
Citations
14
Type
Article

These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

abstract license unknown

Gemcitabine (GEM) is commonly used as the first-line chemotherapeutic agent for treating pancreatic cancer (PC) patients. However, drug resistance is a major hurdle in GEM-based chemotherapy for PC. … Excerpt only: this text is the publisher’s. Read it in full at the source.